Vertex Pharmaceuticals Initiates Phase 3 Registration Program for…
The VX-770 registration program will consist of three clinical trials, including a primary 48-week Phase 3 trial that is currently open to enrollment of patients aged 12 years and older who carry the G551D mutation on at least one allele.
No Comments
RSS feed for comments on this post.
by Raelene
